February 16th 2024
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Community Practice Connections™: What’s Next for Patients with Breast Cancer, and How Can We Effectively Optimize PARP-, HER2/3-, and TROP2-Targeted Regimens in Treatment Plans?
View More
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Pexidartinib Supported by FDA's ODAC for Tenosynovial Giant Cell Tumors
May 14th 2019A scheduled meeting of the FDA's Oncologic Drugs Advisory Committee supported the indication of pexidartinib as a treatment for adult patients with symptomatic tenosynovial giant cell tumor. The panel voted 12 to 3 in favor of the CSF1R inhibitor.
Read More
Pomalidomide Receives FDA Breakthrough Designation for Kaposi Sarcoma
May 13th 2019Pomalidomide was granted a breakthrough designation by the FDA for use as treatment for both patients with HIV-positive Kaposi sarcoma who have had prior chemotherapy and patients with HIV-negative Kaposi sarcoma.
Read More
Olaratumab to Be Withdrawn From Market for Soft Tissue Sarcoma After Missing Primary Endpoint
April 30th 2019The PDGFRα antagonist olaratumab (Lartruvo) will be withdrawn from the market for the treatment of patients with advanced soft tissue sarcoma due to disappointing findings in the phase III ANNOUNCE trial, according to Eli Lilly and Company.
Read More
MEK Inhibitor Granted Breakthrough Designation for NF1 Plexiform Neurofibromas
April 1st 2019The FDA has granted a breakthrough therapy designation to the investigational agent selumetinib for the treatment of pediatric patients ≥3 years old with symptomatic and/or progressive, inoperable neurofibromatosis type 1
Read More
CAR T-Cell Therapy and Lymphodepletion Demonstrates Early Activity in Advanced Sarcoma
April 1st 2019In phase I findings presented during the 2019 AACR Annual Meeting, HER2-directed CAR T-cell therapy and lymphodepletion chemotherapy was found to be safe and effective as a treatment for pediatric and adult patients with advanced HER2-positive sarcoma.
Read More
Positive Correlation With Patient-Reported Outcomes Seen in Phase III ENLIVEN Trial
January 24th 2019Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Watch
Olaratumab Combination Misses OS Endpoint for Sarcoma in Phase III Trial
January 23rd 2019The primary endpoint of overall survival benefit with the combination of olaratumab plus doxorubicin was not met for patients with advanced or metastatic soft tissue sarcoma in the phase III ANNOUNCE clinical trial.
Read More
Abemaciclib Demonstrates Promising Clinical Activity in Dedifferentiated Liposarcoma
November 20th 2018Results from a phase II trial of abemaciclib presented at the 2018 CTOS Annual Meeting showed that the majority of patients with dedifferentiated liposarcoma remained progression free at 12 weeks following abemaciclib treatment.
Read More
Olaratumab Added to Doxorubicin-based Chemo May Improve Safety in Select Patients With Advanced STS
November 20th 2018The addition of olaratumab to doxorubicin-based chemotherapy resulted in similar response and stable disease rates between patients with advanced soft tissue sarcoma and a good performance status, but provided an improved safety profile that favored the olaratumab cohort, according to results reported at the 2018 CTOS Annual Meeting.
Read More
Avapritinib Demonstrates Potentially Practice Changing Results in GIST
November 19th 2018Avapritinib showed substantial clinical activity in patients with gastrointestinal stromal tumors with <em>KIT</em> and <em>PDGFRA</em> mutations, according to findings from the phase I NAVIGATOR trial presented at the 2018 CTOS Annual Meeting. To date, patients with GIST who harbor these mutations have typically been resistant to all available therapies.
Read More
Crizotinib Demonstrates Important Clinical Activity in Advanced, Inoperable IMFT
November 17th 2018Half of the patients with inflammatory myofibroblastic tumor (IMFT) demonstrated a response to crizotinib (Xalkori), according to results from the EORTC phase II "CREATE" study 90101 reported at the 2018 CTOS Annual Meeting.
Read More
Avapritinib Could Deliver Precision Medicine to Patients With GIST, Says Heinrich
November 17th 2018The investigational agent avapritinib demonstrated encouraging response rates in patients with advanced gastrointestinal stromal tumors and PDGFRα D842V-driven GIST, according to findings presented during the 2018 Annual Meeting of the Connective Tissue Oncology Society in Rome, Italy.
Read More
Treatment Type and Cognitive Impairment in GIST
November 16th 2018During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.
Watch
Crizotinib Holds Promise for Treating IMFT, Says Schoffski
November 15th 2018Patrick Schöffski, MD, MPH, discussed the key findings from the CREATE trial, the next steps for research into inflammatory myofibroblastic tumor, and the regulatory challenges for approval of drugs for rare cancers.
Read More
Practice-Changing Survival Improvements Seen With Maintenance Chemo in Pediatric Rhabdomyosarcoma
June 4th 2018Practice-changing improvements in disease-free survival and overall survival rates were seen for patients with pediatric rhabdomyosarcoma with the addition of a course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy.
Read More
Larotrectinib Granted FDA's Priority Review for NTRK+ Cancers
May 29th 2018A new drug application for larotrectinib has been granted a priority review by the FDA for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors with an <em>NTRK</em> gene fusion, according to Bayer and Loxo Oncology, the codevelopers of the pan-TRK inhibitor.
Read More
Larotrectinib Excites in TRK Fusion Cancers for Both Adult and Pediatric Patients
April 27th 2018When findings of larotrectinib, a pan-TRK inhibitor co-developed by Bayer and Loxo Oncology, that generated significant excitement for the treatment of both adult and pediatric patients with TRK fusion cancers, were presented during the 2017 ASCO Annual Meeting, the small molecule was lauded as a future standard of care for patients with advanced solid tumors harboring a TRK fusion.
Read More
Crizotinib Reaches 100% Disease Control Rate in ALK+ Inflammatory Myofibroblastic Tumors
April 16th 2018In a precision medicine success story, crizotinib (Xalkori) demonstrated a 50% objective response rate and a 100% disease control rate in patients with <em>ALK</em>-positive advanced, inoperable inflammatory tumors, in findings from the CREATE study presented at the 2018 AACR Annual Meeting.
Read More
Response Rate Tops 90% With Larotrectinib in TRK+ Pediatric Cancers
April 5th 2018According to findings from a phase I/II study published in <em>The Lancet Oncology</em>, there was an “unprecedented” objective response rate of 93% with larotrectinib in patients with TRK fusion–positive solid tumors.
Read More
Expert Discusses Promise of Novel Sarcoma Vaccine and Other Ongoing Research in the Field
March 30th 2018In an interview with <em>Targeted Oncology</em>, Pollack, assistant member, Clinical Research Division, assistant professor, Division of Oncology, University of Washington, and attending physician at Seattle Cancer Care Alliance, discussed some of the advancements his lab is making in the field of sarcoma.
Read More
New Drug Application Completed for Larotrectinib for Solid Tumors Harboring NTRK Gene Fusion
March 27th 2018The new drug application for larotrectinib (LOXO-101) for treatment of patients with locally advanced or metastatic solid tumors that harbor an NTRK gene fusion has been completed.
Read More
Biological Rationale Explained for Continued Investigation of Immunotherapy in Sarcomas
March 22nd 2018In the sarcoma field, the potential benefit of immunotherapy is currently challenged not only by the heterogeneity of each patient, but also by the heterogeneity of each histologic subtype. William D. Tap, MD, discussed the role for immunotherapy in patients with soft tissue sarcomas and gastrointestinal stromal tumors (GISTs) during a presentation at the 2018 ESMO Sarcoma & GIST Symposium.
Read More
Targeted Treatments Showing Early Efficacy in Sarcoma Subtypes
March 21st 2018Following in the footsteps of pazopanib and olaratumab, many targeted therapies are being studied in patients with soft tissue sarcomas to capitalize on the benefits of targeted therapies in sarcomas. Although chemotherapy-driven approaches remain the standard for treatment of sarcomas, many sensitivities to chemotherapies have appeared in patients with sarcoma subtypes. These patients may benefit from targeted therapy approaches.
Read More
Optimal Patient Selection for Denosumab in Giant Cell Tumor of Bone
January 24th 2018Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.
Watch
Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced GISTs
January 22nd 2018Patients with heavily pretreated gastrointestinal stromal tumors responded to treatment with nivolumab (Opdivo) alone and in combination with ipilimumab (Yervoy), according to findings of a randomized phase II study presented at the 2018 Gastrointestinal Cancers Symposium.
Read More
Beckerle Awarded NCI Award for Research on Genetics of Cancer
January 17th 2018Mary C. Beckerle, PhD, has been awarded the Alfred G. Knudson Award in Cancer Genetics by the National Cancer Institute (NCI). She received her award at the NCI’s Maryland headquarters before delivering a lecture on tumor biology.
Read More
Novel Kinase Inhibitor Shows Encouraging Disease Control in Heavily Pretreated GIST
December 22nd 2017A novel kinase switch control inhibitor, DCC-2618, demonstrated an encouraging disease control rate (DCR) of 76% at 12 weeks in heavily pretreated patients with gastrointestinal stromal tumors (GIST) treated with a daily ≥100-mg dose, according to findings of a phase I first-in-human, dose-escalation trial.
Read More
Results for Denosumab in Patients With Giant Cell Tumor of Bone
December 20th 2017Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses efficacy results for denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).
Watch